Biotechnology
Compare Stocks
5 / 10Stock Comparison
XAGE vs UNH vs CVS vs AMWL vs HIMS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Information Services
Medical - Equipment & Services
XAGE vs UNH vs CVS vs AMWL vs HIMS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Information Services | Medical - Equipment & Services |
| Market Cap | $7M | $344.90B | $115.54B | $133M | $7.30B |
| Revenue (TTM) | $1M | $449.71B | $407.90B | $182M | $2.35B |
| Net Income (TTM) | $-6M | $12.04B | $2.93B | $-88M | $128M |
| Gross Margin | 54.6% | 18.8% | 13.9% | 38.7% | 69.7% |
| Operating Margin | -401.0% | 4.2% | 1.5% | -50.6% | 4.6% |
| Forward P/E | — | 20.7x | 12.4x | — | 58.3x |
| Total Debt | $639K | $78.39B | $93.59B | $5M | $1.12B |
| Cash & Equiv. | $157K | $24.36B | $8.51B | $182M | $229M |
XAGE vs UNH vs CVS vs AMWL vs HIMS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Longevity Health Ho… (XAGE) | 100 | 0.1 | -99.9% |
| UnitedHealth Group … (UNH) | 100 | 97.2 | -2.8% |
| CVS Health Corporat… (CVS) | 100 | 106.7 | +6.7% |
| American Well Corpo… (AMWL) | 100 | 4.4 | -95.6% |
| Hims & Hers Health,… (HIMS) | 100 | 374.9 | +274.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XAGE vs UNH vs CVS vs AMWL vs HIMS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
XAGE ranks third and is worth considering specifically for growth.
- 139.4% revenue growth vs AMWL's -2.0%
UNH is the clearest fit if your priority is dividends.
- 2.3% yield, 25-year raise streak, vs CVS's 3.0%, (3 stocks pay no dividend)
CVS carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 0 yrs, beta 0.13, yield 3.0%
- Beta 0.13, yield 3.0%, current ratio 0.84x
- Lower P/E (12.4x vs 58.3x)
- Beta 0.13 vs HIMS's 2.48, lower leverage
AMWL is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.31, Low D/E 1.8%, current ratio 3.37x
HIMS is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 188.5% 10Y total return vs UNH's 228.3%
- 5.5% margin vs XAGE's -393.6%
- 6.0% ROA vs XAGE's -173.9%, ROIC 10.7% vs -38.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 139.4% revenue growth vs AMWL's -2.0% | |
| Value | Lower P/E (12.4x vs 58.3x) | |
| Quality / Margins | 5.5% margin vs XAGE's -393.6% | |
| Stability / Safety | Beta 0.13 vs HIMS's 2.48, lower leverage | |
| Dividends | 2.3% yield, 25-year raise streak, vs CVS's 3.0%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +37.4% vs XAGE's -93.1% | |
| Efficiency (ROA) | 6.0% ROA vs XAGE's -173.9%, ROIC 10.7% vs -38.0% |
XAGE vs UNH vs CVS vs AMWL vs HIMS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
XAGE vs UNH vs CVS vs AMWL vs HIMS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HIMS leads in 3 of 6 categories
CVS leads 2 • XAGE leads 0 • UNH leads 0 • AMWL leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HIMS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 308591.6x XAGE's $1M. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to XAGE's -3.9%. On growth, XAGE holds the edge at +19.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1M | $449.7B | $407.9B | $182M | $2.3B |
| EBITDAEarnings before interest/tax | -$6M | $23.2B | $10.5B | -$59M | $164M |
| Net IncomeAfter-tax profit | -$6M | $12.0B | $2.9B | -$88M | $128M |
| Free Cash FlowCash after capex | -$4M | $19.7B | $7.4B | -$42M | $73M |
| Gross MarginGross profit ÷ Revenue | +54.6% | +18.8% | +13.9% | +38.7% | +69.7% |
| Operating MarginEBIT ÷ Revenue | -4.0% | +4.2% | +1.5% | -50.6% | +4.6% |
| Net MarginNet income ÷ Revenue | -3.9% | +2.7% | +0.7% | -48.2% | +5.5% |
| FCF MarginFCF ÷ Revenue | -2.6% | +4.4% | +1.8% | -22.9% | +3.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.8% | +2.0% | +6.2% | -100.0% | +28.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -4.9% | +0.7% | +63.1% | +44.5% | -27.3% |
Valuation Metrics
CVS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 28.7x trailing earnings, UNH trades at a 56% valuation discount to CVS's 65.1x P/E. On an enterprise value basis, CVS's 13.4x EV/EBITDA is more attractive than HIMS's 46.5x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $7M | $344.9B | $115.5B | $133M | $7.3B |
| Enterprise ValueMkt cap + debt − cash | $7M | $398.9B | $200.6B | -$45M | $8.2B |
| Trailing P/EPrice ÷ TTM EPS | -0.64x | 28.72x | 65.14x | -1.34x | 55.43x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 20.71x | 12.39x | — | 58.29x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 17.10x | 13.38x | — | 46.50x |
| Price / SalesMarket cap ÷ Revenue | 132.99x | 0.77x | 0.29x | 0.53x | 3.11x |
| Price / BookPrice ÷ Book value/share | — | 3.40x | 1.53x | 0.52x | 13.50x |
| Price / FCFMarket cap ÷ FCF | — | 21.46x | 14.80x | — | 98.70x |
Profitability & Efficiency
HIMS leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-103 for XAGE. AMWL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), UNH scores 6/9 vs HIMS's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -103.5% | +11.5% | +3.9% | -33.5% | +23.7% |
| ROA (TTM)Return on assets | -173.9% | +3.9% | +1.1% | -25.1% | +6.0% |
| ROICReturn on invested capital | -38.0% | +9.2% | +5.0% | -95.1% | +10.7% |
| ROCEReturn on capital employed | -47.5% | +9.7% | +6.1% | -36.6% | +10.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 5 | 6 | 4 |
| Debt / EquityFinancial leverage | — | 0.77x | 1.24x | 0.02x | 2.07x |
| Net DebtTotal debt minus cash | $481,854 | $54.0B | $85.1B | -$178M | $892M |
| Cash & Equiv.Liquid assets | $157,139 | $24.4B | $8.5B | $182M | $229M |
| Total DebtShort + long-term debt | $638,993 | $78.4B | $93.6B | $5M | $1.1B |
| Interest CoverageEBIT ÷ Interest expense | -293.50x | 4.71x | 2.11x | -239.18x | — |
Total Returns (Dividends Reinvested)
HIMS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $27,393 today (with dividends reinvested), compared to $11 for XAGE. Over the past 12 months, CVS leads with a +37.4% total return vs XAGE's -93.1%. The 3-year compound annual growth rate (CAGR) favors HIMS at 33.6% vs XAGE's -89.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +6.3% | +13.6% | +14.7% | +64.3% | -15.4% |
| 1-Year ReturnPast 12 months | -93.1% | +0.8% | +37.4% | +14.5% | -45.0% |
| 3-Year ReturnCumulative with dividends | -99.9% | -17.8% | +41.2% | -80.2% | +138.6% |
| 5-Year ReturnCumulative with dividends | -99.9% | -0.9% | +19.8% | -96.9% | +173.9% |
| 10-Year ReturnCumulative with dividends | -99.9% | +228.3% | +6.6% | -98.3% | +188.5% |
| CAGR (3Y)Annualised 3-year return | -89.8% | -6.3% | +12.2% | -41.7% | +33.6% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than HIMS's 2.48 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 99.6% from its 52-week high vs XAGE's 3.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.92x | 0.60x | 0.13x | 1.31x | 2.48x |
| 52-Week HighHighest price in past year | $8.27 | $390.92 | $90.88 | $9.15 | $70.43 |
| 52-Week LowLowest price in past year | $0.23 | $234.60 | $58.35 | $3.71 | $13.74 |
| % of 52W HighCurrent price vs 52-week peak | +3.9% | +97.2% | +99.6% | +87.1% | +40.1% |
| RSI (14)Momentum oscillator 0–100 | 48.5 | 76.9 | 70.0 | 72.3 | 50.2 |
| Avg Volume (50D)Average daily shares traded | 1K | 7.9M | 7.5M | 60K | 34.8M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: UNH as "Buy", CVS as "Buy", AMWL as "Hold", HIMS as "Hold". Consensus price targets imply 6.8% upside for CVS (target: $97) vs -27.9% for AMWL (target: $6). For income investors, CVS offers the higher dividend yield at 2.95% vs UNH's 2.29%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | — | $385.43 | $96.75 | $5.75 | $26.20 |
| # AnalystsCovering analysts | — | 52 | 41 | 15 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | +2.3% | +3.0% | — | — |
| Dividend StreakConsecutive years of raises | — | 25 | 0 | — | — |
| Dividend / ShareAnnual DPS | — | $8.70 | $2.67 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.6% | 0.0% | +0.0% | +1.2% |
HIMS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 2 (Valuation Metrics, Risk & Volatility). 1 tied.
XAGE vs UNH vs CVS vs AMWL vs HIMS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is XAGE or UNH or CVS or AMWL or HIMS a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -2. 0% for American Well Corporation (AMWL). UnitedHealth Group Incorporated (UNH) offers the better valuation at 28. 7x trailing P/E (20. 7x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — XAGE or UNH or CVS or AMWL or HIMS?
On trailing P/E, UnitedHealth Group Incorporated (UNH) is the cheapest at 28.
7x versus CVS Health Corporation at 65. 1x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — XAGE or UNH or CVS or AMWL or HIMS?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +173. 9%, compared to -99. 9% for Longevity Health Holdings Inc. (XAGE). Over 10 years, the gap is even starker: UNH returned +228. 3% versus XAGE's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — XAGE or UNH or CVS or AMWL or HIMS?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
13β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 1811% more volatile than CVS relative to the S&P 500. On balance sheet safety, American Well Corporation (AMWL) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — XAGE or UNH or CVS or AMWL or HIMS?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -2. 0% for American Well Corporation (AMWL). On earnings-per-share growth, the picture is similar: American Well Corporation grew EPS 57. 1% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — XAGE or UNH or CVS or AMWL or HIMS?
Hims & Hers Health, Inc.
(HIMS) is the more profitable company, earning 5. 5% net margin versus -206. 1% for Longevity Health Holdings Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -99. 3% for XAGE. At the gross margin level — before operating expenses — XAGE leads at 87. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is XAGE or UNH or CVS or AMWL or HIMS more undervalued right now?
On forward earnings alone, CVS Health Corporation (CVS) trades at 12.
4x forward P/E versus 58. 3x for Hims & Hers Health, Inc. — 45. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CVS: 6. 8% to $96. 75.
08Which pays a better dividend — XAGE or UNH or CVS or AMWL or HIMS?
In this comparison, CVS (3.
0% yield), UNH (2. 3% yield) pay a dividend. XAGE, AMWL, HIMS do not pay a meaningful dividend and should not be held primarily for income.
09Is XAGE or UNH or CVS or AMWL or HIMS better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
13), 3. 0% yield). Longevity Health Holdings Inc. (XAGE) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +6. 6%, XAGE: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between XAGE and UNH and CVS and AMWL and HIMS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: XAGE is a small-cap quality compounder stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap quality compounder stock; AMWL is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock. UNH, CVS pay a dividend while XAGE, AMWL, HIMS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.